Inovio Pharmaceuticals (NASDAQ:INO – Get Free Report) and Shattuck Labs (NASDAQ:STTK – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, profitability, risk, analyst recommendations, dividends, institutional ownership and valuation.
Insider and Institutional Ownership
26.8% of Inovio Pharmaceuticals shares are owned by institutional investors. Comparatively, 58.7% of Shattuck Labs shares are owned by institutional investors. 1.7% of Inovio Pharmaceuticals shares are owned by company insiders. Comparatively, 8.8% of Shattuck Labs shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Profitability
This table compares Inovio Pharmaceuticals and Shattuck Labs’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Inovio Pharmaceuticals | N/A | -669.94% | -73.97% |
| Shattuck Labs | N/A | -43.57% | -40.90% |
Risk and Volatility
Inovio Pharmaceuticals has a beta of 1.61, indicating that its stock price is 61% more volatile than the S&P 500. Comparatively, Shattuck Labs has a beta of 1.09, indicating that its stock price is 9% more volatile than the S&P 500.
Earnings & Valuation
This table compares Inovio Pharmaceuticals and Shattuck Labs”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Inovio Pharmaceuticals | $60,000.00 | 1,498.96 | -$84.95 million | ($0.91) | -0.96 |
| Shattuck Labs | $1.00 million | 555.99 | -$48.81 million | ($0.51) | -10.86 |
Shattuck Labs has higher revenue and earnings than Inovio Pharmaceuticals. Shattuck Labs is trading at a lower price-to-earnings ratio than Inovio Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a summary of current ratings and recommmendations for Inovio Pharmaceuticals and Shattuck Labs, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Inovio Pharmaceuticals | 1 | 2 | 5 | 0 | 2.50 |
| Shattuck Labs | 1 | 0 | 9 | 3 | 3.08 |
Inovio Pharmaceuticals currently has a consensus target price of $3.17, suggesting a potential upside of 264.07%. Shattuck Labs has a consensus target price of $13.70, suggesting a potential upside of 147.29%. Given Inovio Pharmaceuticals’ higher possible upside, equities research analysts plainly believe Inovio Pharmaceuticals is more favorable than Shattuck Labs.
Summary
Shattuck Labs beats Inovio Pharmaceuticals on 10 of the 14 factors compared between the two stocks.
About Inovio Pharmaceuticals
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade dysplasia; INO-3107 for HPV-related recurrent respiratory papillomatosis and is under Phase 1/2 trial; INO-3112 for the treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma and is under Phase 2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under Phase 1b trial; INO-4800 for COVID-19 and is under Phase 3 trial; and INO-6160 for the treatment of human immunodeficiency virus and is under Phase 1 trial. Its partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, Defense Advanced Research Projects Agency, The U.S. Department of Defense, HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.
About Shattuck Labs
Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. Shattuck Labs, Inc. was incorporated in 2016 and is headquartered in Austin, Texas.
Receive News & Ratings for Inovio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
